Bioporto A/S logo

BIOPOR - Bioporto A/S News Story

DKK5.21 -0.2  -3.0%

Last Trade - 3:59pm

Sector
Industrials
Size
Small Cap
Market Cap £167.6m
Enterprise Value £156.3m
Revenue £2.71m
Position in Universe 759th / 1830

BRIEF-Bioporto Announces CE Mark Of Near-Patient Test For Kidney Injury

Wed 30th December, 2020 2:59pm
Dec 30 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * REG-BIOPORTO ANNOUNCES CE MARK OF NEAR-PATIENT TEST FOR
KIDNEY
INJURY AND MILESTONES FOR GRAD PLATFORM TECHNOLOGY
    * OBTAINED CE MARKING IN EU FOR ITS NGALDS, A NOVEL
GRAD-BASED
TEST FOR NEAR-PATIENT MEASUREMENT OF NGAL, AND ANNOUNCES
COMMERCIAL LAUNCH
    * ITS NOVEL SARS-COV-2 RAPID TEST, ALSO BASED ON
GRAD-PLATFORM, IS
UNDERGOING CLINICAL TESTING AT UNIVERSITY OF CALIFORNIA, DAVIS

Source text for Eikon:  ID:nGNE9wLFDc 
Further company coverage:  BIOPOR.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.